Robert V. Market
Mr. Market is an Assistant Director in the Wafic Said Molecular Cardiology Research Laboratories at the Texas Heart Institute and Intellectual Property Manager for the Office of Research Administration. He has over 20 years of drug discovery experience. He is also licensed to practice law in the State of Texas and before the USPTO. Currently, he also aids in the prosecution of patent applications generated through the institute.
See PublicationsTexas Heart Institute Positions
- Assistant Director, Molecular Cardiology Research
- Intellectual Property Manager, Office of Research Administration
Interests
- Non-invasive diagnostic imaging technologies
Publications
Hickman, A., Koetsier, J., Kurtanich, T. et al. (2022). LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. J Clin Invest 132, e154152. https://doi.org/10.1172/JCI154152.
Lokugamage, N., Chowdhury, I. H., Biediger, R. J. et al. (2021). Use of a small molecule integrin activator as a systemically administered vaccine adjuvant in controlling Chagas disease. NPJ Vaccines 6, 114. https://doi.org/10.1038/s41541-021-00378-5.
Woodside, D. G., Tanifum, E. A., Ghaghada, K. B. et al. (2018). Magnetic resonance imaging of atherosclerotic plaque at clinically relevant field strengths (1T) by targeting the integrin α4β1. Sci Rep 8, 3733. https://doi.org/10.1038/s41598-018-21893-x.
Wu, C., Decker, E. R., Blok, N. et al. (1999). Endothelin antagonists: substituted mesitylcarboxamides with high potency and selectivity for ET(A) receptors. J Med Chem 42, 4485–4499
Scott, I. L., Market, R. V., DeOrazio, R. J. et al. (1999). Stereospecific α-d-mannosylation. Carbohydrate Research 317, 210–216. https://doi.org/10.1016/S0008-6215(99)00065-8.
Dupré, B., Bui, H., Scott, I. L. et al. (1996). Glycomimetic selectin inhibitors: (α-D-mannopyranosyloxy)methylbiphenyls. Bioorganic & Medicinal Chemistry Letters 6, 569–572. https://doi.org/10.1016/0960-894X(96)00071-6.
Kogan, T. P., Dupré, B., Keller, K. M. et al. (1995). Rational design and synthesis of small molecule, non-oligosaccharide selectin inhibitors: (α-D-mannopyranosyloxy)biphenyl-substituted carboxylic acids. J Med Chem 38, 4976–4984
Recent News
Texas Heart Institute’s molecular discovery at the heart of a new vaccine development program
A promising molecular technology co-invented by scientists at the Texas Heart Institute and 7 Hills could soon enhance the effectiveness...
Texas Heart Institute Discovery to Enhance the Immune System Moves Closer to Clinical Testing
A promising technology invented at the Texas Heart Institute is one step closer to being tested in a clinical study...
